Obesity and Dyslipidemia.
Nussbaumerova B, Rosolova H.
Curr Atheroscler Rep. 2023 Dec;25(12):947-955. doi: 10.1007/s11883-023-01167-2. Epub 2023 Nov 18.
Obesity and dyslipidemia.
Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V.
Metabolism. 2019 Mar;92:71-81. doi: 10.1016/j.metabol.2018.11.005. Epub 2018 Nov 14.
Metabolic syndrome update.
Grundy SM.
Trends Cardiovasc Med. 2016 May;26(4):364-73. doi: 10.1016/j.tcm.2015.10.004. Epub 2015 Oct 31.
Dyslipidemia in obesity: mechanisms and potential targets.
Klop B, Elte JW, Cabezas MC.
Nutrients. 2013 Apr 12;5(4):1218-40. doi: 10.3390/nu5041218.
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.
Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N.
Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi: 10.1038/s41392-024-01951-9.
Obesity and dyslipidemia in early life: Impact on cardiometabolic risk.
Zeljkovic A, Vekic J, Stefanovic A.
Metabolism. 2024 Jul;156:155919. doi: 10.1016/j.metabol.2024.155919. Epub 2024 Apr 21.
The role of mitochondrial DNA copy number in cardiometabolic disease: a bidirectional two-sample mendelian randomization study.
Qin P, Qin T, Liang L, Li X, Jiang B, Wang X, Ma J, Hu F, Zhang M, Hu D.
Cardiovasc Diabetol. 2024 Jan 28;23(1):45. doi: 10.1186/s12933-023-02074-1.
Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.
Bays HE, Kirkpatrick CF, Maki KC, Toth PP, Morgan RT, Tondt J, Christensen SM, Dixon DL, Jacobson TA.
J Clin Lipidol. 2024 May-Jun;18(3):e320-e350. doi: 10.1016/j.jacl.2024.04.001. Epub 2024 Apr 24.
Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia.
Yousri NA, Suhre K, Yassin E, Al-Shakaki A, Robay A, Elshafei M, Chidiac O, Hunt SC, Crystal RG, Fakhro KA.
Diabetes. 2022 Feb 1;71(2):184-205. doi: 10.2337/db21-0490.
Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.
Jung UJ, Choi MS.
Int J Mol Sci. 2014 Apr 11;15(4):6184-223. doi: 10.3390/ijms15046184.
